Sat.Aug 06, 2022 - Fri.Aug 12, 2022

article thumbnail

Woman of the Week: COTA’s Miruna Sasu

PharmaVoice

Miruna Sasu is on a mission to use real world data to help wipe out cancer. She believes this audacious goal is within reach, and as president and CEO of COTA, she is inspiring her team to create a “path to care” for oncology patients.

290
290
article thumbnail

This week’s reading list: All the reasons the Senate-passed drug pricing bill is bad policy

PhRMA

Last weekend, the Senate passed the Inflation Reduction Act which includes dangerous price-setting provisions. The bill now heads to the House for consideration, where it is not too late for them to stand up for patients and medical innovation by opposing the bill.

246
246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Study: Green Tea Extract Reduces Blood Sugar Levels, Improves Gut Health

Pharmacy Times

Investigators found that the health risks linked to the condition known as metabolic syndrome could be diminished by green tea’s anti-inflammatory benefits in the gut.

174
174
article thumbnail

The potential of virtual reality-based therapy for serious mental disorders

Pharmaceutical Technology

In June this year, it was announced that the US Food and Drug Administration (FDA) had granted UK-based OxfordVR a breakthrough device designation for its gameChangeVR treatment to deliver immersive cognitive behaviour therapy (CBT) to people suffering from schizophrenia and other mental illnesses. The FDA’s breakthrough device programme is for medical devices or device-led combination products that provide more effective treatment or diagnosis of diseases.

FDA 141
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

How real world evidence is impacting rare disease drug development

PharmaVoice

[link]

245
245
article thumbnail

Making coupons count for patients with HIV

PhRMA

Despite having insurance, too many patients with HIV face high out-of-pocket costs for brand medicines. This is largely driven by insurer-imposed barriers that shift the cost of life-saving care onto patients.

Insurance 237

More Trending

article thumbnail

AI Opens Door To Improving Patient Experience

PharmExec

The technology is not just about digital enablement anymore.

141
141
article thumbnail

As pharma M&A ramps up, U.S. execs are bullish on more deals

PharmaVoice

What top executives at Merck, Pfizer and more are saying about M&A as they move into the second half of the year.

242
242
article thumbnail

New survey: Voters seriously concerned about fine print in reconciliation bill

PhRMA

With a final vote in Congress expected on a reconciliation spending bill, a new Morning Consult survey explores what this legislation actually does – and does not do – and finds that voters are skeptical of its impact on inflation, worried about the consequences of Medicare “negotiation” and concerned the bill doesn’t do enough to help make medicines affordable for patients.

236
236
article thumbnail

Study to Evaluate Efficacy of Telehealth Cognitive Behavioral Therapy for Migraine

Pharmacy Times

Study will analyze whether cognitive behavioral therapy telehealth can lower headache days and disability as effectively as cognitive behavioral therapy plus a preventive medication for migraine.

149
149
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

The Silver Lining Of Innovation in Genetic Medicine

PharmExec

Failed efforts do not overshadow field’s progress, resolve.

132
132
article thumbnail

Turning harp seal contraceptives into a ‘new genre’ of cancer treatments

PharmaVoice

With Andrew Hall at its helm, IMV has evolved an animal contraceptive into a unique drug delivery platform aimed at creating targeted cancer immunotherapies for humans.

147
147
article thumbnail

Value assessment should include all aspects of value that matter to patients

PhRMA

We need to move toward a more value-driven health care system that centers around patients’ needs. Sound evidence can help guide us toward that, and we’re committed to developing tools to help patients, physicians and others make informed decisions.

236
236
article thumbnail

Second Booster Protects Against Breakthrough COVID-19 Variant Infections in Health Care Workers

Pharmacy Times

Health care workers who got 4 total doses against COVID-19, 2 doses of which are boosters, experienced more than 10% lower breakthrough infection rate than those with only 3 total doses.

145
145
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

The Price of Innovation: ‘Paying for a Cure’ Remains Costly Proposition

PharmExec

Curative-type therapies offer great hope in further transforming treatments for cancer and other diseases, but addressing the economics of these products—and ultimately the cost-benefit equation—is daunting. What is being done to smooth the path for pricing and reimbursement?

119
119
article thumbnail

Are Big Pharma CEOs earning their pay?

PharmaVoice

While compensation packages at the top may not always reflect value, it’s not necessarily an industry-wide problem.

Packaging 147
article thumbnail

FDA grants Fast-Track status for Relmada’s major depressive disorder therapy

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted Fast-Track designation to Relmada Therapeutics’ REL-1017 as a single agent to treat major depressive disorder (MDD). A new chemical entity and NMDA receptor (NMDAR) channel blocker, REL-1017 acts on hyperactive channels while preserving physiological glutamatergic neurotransmission. Presently, the therapy is being analysed in late-stage studies.

FDA 119
article thumbnail

Using Immunoinformatics to Create a Clostridium Difficile Vaccine

Pharmacy Times

Immunoinformatics allows researchers to develop vaccines without microbial culturing, thus saving time and money.

Vaccines 139
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

A World of Opportunity

PharmExec

Marie-France Tschudin, president, innovative medicines international, and chief commercial officer at Novartis, taps into life lessons to help bring therapies to people in novel ways­.

116
116
article thumbnail

Despite AbbVie’s Botox prowess, underdog Galderma has leveraged soft skills to succeed in aesthetics

PharmaVoice

Galderma may not have the biggest name in aesthetics, but as the sector grows past pandemic lows, the company is relying on its people to build a loyal customer base.

130
130
article thumbnail

Brexit fallout continues with batch testing concerns

Pharmaceutical Technology

More than a year and a half after the Brexit deal came into effect, the UK’s pharmaceutical industry is still trying to determine the likely impacts. In principle, the deal could create new opportunities for British pharma companies – not least the chance to work under a more supportive regulatory framework. However, in practice we are seeing a climate of real uncertainty.

116
116
article thumbnail

New Binding Mechanism Science Driving Therapeutic Insight in Immune-Mediated Diseases

Pharmacy Times

The ability of an anti-interleukin-23 antibody to bind to key immune system components may help neutralize a key driver of inflammation right at its cellular source.

article thumbnail

Pharma Distribution: Carving New Ground

Pharmaceutical Commerce

Pharmaceutical distribution today is anything but monolithic. While companies in this space are grappling with issues ranging from inflation and supply chain disruption to workforce scarcity and DSCSA implementation, there’s still plenty of room for smaller players to stake out part of the terrain to call their own.

116
116
article thumbnail

4 ways to nail the launch of your cell therapy

PharmaVoice

A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.

130
130
article thumbnail

GSK, Sanofi and Haleon ‘facing billions of dollars in Zantac liability’

pharmaphorum

GSK, its consumer health spin-off Haleon and Sanofi could be on the hook for billions of dollars in potential damages over Zantac, a gastrointestinal drug pulled from the market in 2020 after it was linked to cases of cancer. That’s the conclusion of analysts at Morgan Stanley, Deutsche Bank and UBS, who have all issued research notes drawing attention to the issue, which has remained largely off the radar since sales of Zantac (ranitidine) were halted.

FDA 105
article thumbnail

CDC Study Finds Second COVID-19 Booster Defends Against Omicron Variants

Pharmacy Times

The CDC published a new study, which found that a second mRNA booster shot would be effective against the Omicron variants of COVID-19.

132
132
article thumbnail

US FDA approves Daiichi Sankyo-AstraZeneca’s Enhertu for lung cancer

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted approval for Daiichi Sankyo and AstraZeneca ’s Enhertu (fam-trastuzumab deruxtecan-nxki) to treat unresectable or metastatic non-small cell lung cancer (NSCLC) in adults. The treatment is indicated for such patients whose tumours have activating HER2 (ERBB2) mutations and previously received systemic therapy. .

FDA 105
article thumbnail

Regions On Rise: Life Sciences Across US

Pharmaceutical Commerce

Exploring the competitive and unique offerings in three of the US’s lower-cost economic development regions—and how success in these areas has been boosted by COVID.

105
105
article thumbnail

Cumulus’ gamified dry EEG system tops lab monitoring in trial

pharmaphorum

An at-home electroencephalogram (EEG) headset used alongside game-like cognitive tasks developed by UK company Cumulus Neuroscience has been shown to be more effective than lab-based EEG monitoring in a clinical trial. The ‘dry’ EEG system provides an alterative to lab EEG systems using wet electrodes that require gel application, skin preparation, and clean-up procedures that can impede use of the technology in real-world settings.

FDA 105
article thumbnail

Regeneron’s REGM5678 Combination Shows Positive Results for Prostate Cancer

Pharmacy Times

Preliminary data from the ongoing dose-escalation portion of the clinical trial, show dose-dependent anti-tumor activity when combined with standard-dose Libtayo.

132
132
article thumbnail

Is albumin the key to successful nasal vaccines?

European Pharmaceutical Review

According to researchers, binding nasal vaccine antigens to albumin enables them to bypass mucosal barriers, and could lead to better protection against pathogens like HIV and Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2; the virus that causes COVID-19). The University of Minnesota researchers tested the technology on mice and non-human primates and found that the vaccine generated strong immune responses, paving the way for further study and development of nasal vaccines.

Vaccines 105
article thumbnail

The drugs don’t work (and other mental health myths)

The Guardian - Pharmaceutical Industry

Our attitudes to mental health are changing but much of the stigma that surrounds conditions such as schizophrenia remains – along with some enduring and often damaging untruths There can be little doubt that public attitudes to mental health have already turned a corner. Just consider the sheer number of public figures – from Robbie Williams and Lady Gaga to Baroness Davidson – who have opened up about their struggles.

99
article thumbnail

Pfizer to acquire sickle cell disease specialist for $5.4b USD

Outsourcing Pharma

Biopharmaceutical company Global Blood Therapeutics specializes in conditions that often disproportionately impact underrepresented communities, such as SCD.

99